GretchMick (@GretchMick) header
GretchMick (@GretchMick) profile picture

Just trying to keep up...🏃‍♀️🏋️‍♂️ 🏌🏽‍♀️ CrossFit L2 Trainer~Beating Cancer with @immunitybio

Joined March 2022
Photo by GretchMick (@GretchMick)Photo by GretchMick (@GretchMick)Photo by GretchMick (@GretchMick)Photo by GretchMick (@GretchMick)Photo by GretchMick (@GretchMick)Photo by GretchMick (@GretchMick)
Big news for bladder cancer patients! FDA just expanded approval of Anktiva with BCG for adults with BCG-unresponsive, high-grade papillary-only NMIBC — the first treatment approved for this group. This is a first, and that matters. Evidence from a closely related form of bladder cancer supported the approval. fda.gov/drugs/resources-info…
40
99
31
430
54,045
Best of wishes Michael and Congratulations . There are millions of patients with cancer worldwide who are in complete remission. The next frontier is to develop therapies strengthening the immune system to prevent recurrence in these over 15 million patients in the USA alone, and drive long term durable freedom from cancer to win the war. Incremental short term duration of response should no longer be an acceptable outcome. The therapies to address and maintain cancer free status are now here……..the orchestration of the immune system, the identification of tumor DNA in the peripheral blood, the easy measurement of the NK and T cell levels in the peripheral blood count, the sophistication of next gen PET/ MRI/ CT scans, the ability to grow and store activated NK cells, the ability to identify tumor educated T cells, the new knowledge of camelid derived heavy chain single domain antibodies and the ability to precisely target radioactive ligands, to precisely target CART and CarNK and CAR-iNKT cells. These immunotherapy advances are all here today and in various stages of clinical trials. The oncology community will enter this next generation of paradigm change. The need to establish these diagnostic and therapeutic combinations as IMMUNOTHERAPY 2.0 is both urgent and exhilarating. This was the subject of my one hour talk with NIH and NCI and the decade of collaboration with Jeffrey Schlom and James Gulley to develop a cancer vaccine. Hope to release the talk once I receive the video recording and obtain clearance to make it public. We are closer than ever.
Caputo appointed to President’s Cancer Panel “I’ve been blessed with colleagues who are interested in my cancer battle, and it’s not over. My cancer is gone, but Susie said it best: now I have to rebuild what treatment took from me.” - The Cancer Letter cancerletter.com/white-house…
48
133
14
898
138,834
Brandon Clark has fought Stage IV colon cancer for five years. He travels to California every 3 weeks for an immunotherapy trial, while receiving care at Siteman Center in St. Louis. Please donate or share via the GoFundMe page to support treatment and his 3 boys. Thank you. #ColonCancer gofund.me/86de89de5
4
12
2
30
25,312
Forcing a vaccine, or any medical intervention, on another human being is a violation of the fundamental right to bodily autonomy. And when people say, “No one is forcing you”: If a child cannot attend school without complying, cannot go to summer camp, cannot participate in sports, or is excluded from ordinary life because their parents declined a medical intervention, that is not meaningful consent. It is coercion. Consent obtained under threat of exclusion, punishment or loss of opportunity is not freely given consent. Medical decisions belong to individuals and families. Not schools, employers, corporations or the state. There should never be a penalty attached to saying no, PERIOD.
238
2,732
157
6,864
73,191
GretchMick retweeted
$IBRX My personal opinion is that IBRX should be approved for Lymphopenia now. There are no safety issues with IBRX. So why not? Is there enough data to approve it? I think enough. This FDA is really a fucked up mess. They are clowning around approving bullshit stuff while Lymphopenia is f-ing huge. Is there anyone out there that is even in clinical trials to cure Lymphopenia. No one. Except us. Our FDA is a fucked up mess. This shit is starting to seriously piss me off. Is there anything that trump can do? And Sepsis is another one. Jesus, what a mess.
14
19
1
146
5,051
GretchMick retweeted
What's it going to take for the FDA to cut the red tape? #ANKTIVA and natural killer (NK) cell therapy are already delivering miracles—activating the body's own immune system to fight cancer where other treatments failed. My husband Andrew's remarkable recovery from GBM (multiple clean MRIs, healthy tissue regrowth) is living proof. Hundreds of patients are reaching out for this hope. It's time to unleash these therapies into every qualified hospital nationwide. Expand access now through CNPV vouchers, Right to Try, and streamlined approvals. No more bureaucracy standing between patients and lifesaving care. Let's save lives. Let's kill cancer. Share if you or someone you love deserves better options. Tag your reps. Demand action. @US_FDA @DrPatrick @bullishbruk #ANKTIVA #NKCellTherapy
30
99
12
354
9,263
GretchMick retweeted
$IBRX ANKTIVA (N-803) should be considered for inclusion iin the Commissioner’s National Priority Voucher pilot program, shifting the paradigm from tumor-specific targeting to a pan-tumor immune-reconstitution strategy. Please write a comment on stkt.co/G5KnZ4n3
4
8
77
2,251
If you missed the FDA hearing about the Commissioner’s National Priority Voucher Program where @LoriMills4CA42 I gave comments, here is what I said: Good afternoon, distinguished panelists and members of the FDA. As Henry Ford said: “We need a faster horse.”  My name is Karol Hansen. I am a Stage IV breast cancer patient with Mets to the bones. I have been fighting cancer for 10 years. In that time, I have undergone chemotherapy twice, radiation three times, and more than 25 surgeries. The cancer has recurred over 11 times. 10 years ago, Nuelasta was prescribed to me before I even had neutropenia because it’s medically known that chemotherapy causes Netropenia. Neutrophils are an inherent part of the body’s immune system that provide rapid, broad, innate protection against infection and injury. Lymphocytes form the core of the adaptive immune system and are responsible for precise, targeted and long-lasting immunity. Neulasta, and its biosimilars, is given prophylactically to protect neutrophils. ANK TIVA, manufactured by Immunity Bio in California protects lymphocytes, but it is NOT YET approved by the FDA for all cancer types. During these years of relentless treatment my Absolute Lymphocyte Count remains critically low — below the threshold associated with increased infections, weakness, treatment failure, and shortened survival. There are millions of cancer patients whose ALC looks just like mine. RIGHT NOW, at the Chan Soon-Shiong Institute for Medicine there are 15,000 patients waiting in line to receive ANK TIVA. ANK TIVA is the first therapy designed to restore and activate lymphocytes through its IL-15 mechanism. It is the missing piece of immune boosting protection — ANK TIVA is the equivalent to lymphocytes as Neulasta is to neutrophils. I have intractable, treatment-resistant cancer that has failed standard therapies. If ANK TIVA had been available as standard supportive care a decade ago, I might have been spared years of immune collapse, repeated recurrences, and the physical and emotional toll of more than 25 surgeries. Now I am out of time, out of strength and out of options. The 15,000 patients waiting for ANK TIVA can only get it if an opening is available in a narrow group of clinical trials or through the Extended Access Program, which the clinic has to process one at a time, on a case by case basis. A VERY SLOW process. It took almost a year for me to get approved. That’s not POLITICS, that’s imminent death for critically ill patients. Ladies and gentlemen, we HAVE the cart, which is ANK TIVA. But, as Henry Ford said, “WE NEED A FASTER HORSE!”  The Commissioner’s National Priority Voucher Program IS THAT FASTER HORSE!  Immunity Bio is delivering groundbreaking immune-restoring therapy of ANK TIVA but the FDA needs to approve it as a first line of defense for patients with lymphopenia.  The CNPV Program was created to accelerate exactly these kinds of innovative therapies that address critical unmet needs and can transform patient outcomes. I urge the FDA to prioritize ANK TIVA for full approval and label expansion so that every cancer patient undergoing chemotherapy or radiation can receive lymphocyte support proactively — not as a desperate final measure after years of fighting for survival. It is TIME for a faster horse at the FDA. Streamline the review process. Provide a patient conduit directly to CNPV. Give us a voice. Speed up access to ANK TIVA. Give future patients the CHANCE at a fuller life that I, and others who have died while waiting, have been denied. Thank you for listening to my story and for the work you do every day on behalf of patients like me
53
70
10
304
22,375
I’ll be speaking tomorrow in front of the FDA to advocate for ANKTIVA to be given to all cancer patients as a first line of defense. If you’re interested in this hearing discussing the Commissioner’s National Priority Voucher Program you can watch the hearing on their YouTube channel starting at 1:00 pm Eastern: youtube.com/live/5gS9gJ99Cvk… Approve Anktiva! @LoriMills4CA42 @DrPatrick @richadcock @ImmunityBio @ChiayuChenMD @bullishbruk @USNCG5Rick @tteuscher @GretchMick @Brandon_r_clark @CarnivoreKen @JeffRoseTV @theduffhoneybee @ethan_leffler @Natasha_Buga @megbasham @reborn_amit @shelbysaidthat @Kathryn83970251 @SandyGl88167783
18
41
5
166
29,350
GretchMick retweeted
$IBRX Dr. Pat interview. Worth watching. youtu.be/MAaEG7YP_m0
9
39
5
191
14,255
FDA is holding up approval for Dr. Soon Shiong's Anktiva for papillary bladder cancer. Take a minute to look at the cancer-free statistics from ChatGPT for Merck's Keytruda, which was approved for papillary bladder cancer, vs Anktiva, which has yet to be approved for papillary bladder cancer, despite the fact that Anktiva is the superior drug for this disease. At 24 months: Keytruda: ~30–40% disease-free. Anktiva+BCG ~52% disease-free. At 3 years: 73% of Keytruda patients kept their bladders. 82% of Anktiva + BCG patients kept their bladders. At 3 years: Keytruda overall survival: ~90% Anktiva + BCG overall survival: ~96% Dr. Makary, Dr. Bhattacharya, Sec Kennedy, please do the right thing and approve Anktiva for papillary bladder cancer now. Save more lives. Please help spread the word & retweet this post. @DrMakaryFDA @DrPatrick @ImmunityBio @DrJBhattacharya @ChrisCuomo @SecKennedy @LoriMills4CA42 @tteuscher @CarnivoreKen @julie_bush @bullishbruk @exosome @Johnincarlisle @chrisca70578779
13
56
4
227
10,370
$IBRX A billionaire in his 70s still grinding every day not for headlines, but to push forward treatments for ALC and cancer. He’s taking on big pharma, challenging the system, and staying directly connected to patients sometimes even responding personally to those reaching out for help. That kind of commitment is rare. This isn’t about money it’s about impact, purpose, and changing lives.
3
27
1
182
3,658
March is Colorectal Cancer Awareness Month. As a GI oncologist, there’s something I wish everyone understood: Many of the patients I see with colon cancer never thought they were at risk. Some are in their 40s. Some even younger. Here’s what everyone should know 👇
27
46
3
129
139,107
GretchMick retweeted
This woman got beaten up by ‘biological male’ Imane Khelif. Her Olympics dreams were crushed. Liberal activists defended a man beating her up. She deserves an apology.
249
1,650
68
8,465
70,087
GretchMick retweeted
Dr. Patrick is a polymath and N of 1 biotech pioneer. He is relentless and won’t stop until Immunity Bio makes a huge dent in cancer care. @DrPatrick wsj.com/business/media/the-s…
3
16
143
2,427
"You’re too young for that" is a phrase that's becoming dangerously outdated in medicine. From colon cancer to breast cancer, the age of onset is dropping, and the aggressiveness is rising. Don't wait for "standard" screening ages if you feel something is wrong. You are your own best advocate. @DrKellyVictory
27
152
4
506
16,410
Chemotherapy kills cancer cells. It also kills the immune cells that kill cancer cells. Most of oncology has accepted that trade-off. @DrPatrick never did. He built Anktiva, an IL-15 agonist that activates and expands your NK cells and T cells without triggering the suppressive cells that protect tumors. Saudi Arabia just approved it for lung cancer. First country in the world to do so. I've been using IL-15 intratumorally in combination with other immunotherapy agents for years. What Dr. Soon-Shiong is doing at the systemic level, we're doing at the tumor level. The future of cancer treatment isn't about finding better poisons. It's about unlocking what's already inside you.
🚨: Japanese scientist Patrick Soon-Shiong has designed a treatment that activates body's natural killer cells that fight against cancer cells. Its approved in the U.S. and now Saudi Arabia has also approved it for its public.
Readers added context they thought people might want to know
Patrick Soon-Shiong is South African-born of Chinese descent, not Japanese. Anktiva is approved for bladder cancer in the US and for bladder and lung cancer in Saudi Arabia, not for all cancers. en.wikipedia.org/wiki/Patrick_S… fiercepharma.com/pharma/soon-sh… cancernetwork.com/view/nogapende… immunitybio.com/saudi-fda-gran…
66
1,804
33
8,596
476,521
GretchMick retweeted
Dr. Patrick Soon-Shiong just showed Chris Cuomo dramatic before-and-after brain scans of late-stage tumor patients who failed chemo, radiation, and surgery — achieving complete remission with ANKTIVA. No chemo. No radiation. Tumors shrinking dramatically in months. He says: “We got FDA approval to treat patients who failed everything… and they got complete remissions. It wasn’t a one-off anecdote.” ANKTIVA (nogapendekin alfa inbakicept) is an IL-15 superagonist that activates and proliferates natural killer cells and CD8+ T-cells while avoiding regulatory T-cell suppression, turning the immune system into a targeted cancer-killing force. Clip from this 43-second segment — a potential game-changer for late-stage cases. Is ANKTIVA the breakthrough we’ve been waiting for… or do we need larger trials to confirm? Your thoughts — drop them below. Stay informed. Stay hopeful.
127
1,620
44
5,604
282,481
Only in clown world would @ImmunityBio and their product Anktiva not be approved for all cancers, Lynch, and so much more. $IBRX
This Post is from an account that no longer exists. Learn more
6
25
2
120
6,531